Hem/Onc News

Tagraxofusp-erzs Approved in Blastic Plasmacytoid Dendritic Cell Neoplasm The US Food and Drug Administration (FDA) approved tagraxofusp-erzs (Elzonris, Stemline) on December 21 for blastic plasmacytoid dendritic […]

RT @DrHKantarjian: The field of #BPDCN is rapidly evolving | Our new article by Dr. Pemmaraju @doctorpemm highlights the new era of ta… https://t.co/JSFnWqi49W

11 months ago
RT @ChelseaPinnix: Great summary of the important work that’s been done to improve outcomes in a rare disease. The future is bright.… https://t.co/PmNK5VOwvT

11 months ago
“Blastic Plasmacytoid Dendritic Cell Neoplasm: Emerging Developments and Special Considerations for 2023” by Naveen… https://t.co/EAEfwKrGjU

12 months ago
“Novel Approaches to the Treatment of Multiple Myeloma” by Kathryn T. Maples, PharmD, Sara A. Scott, PharmD, and Sa… https://t.co/9fIXqRSXxe

12 months ago